Similar articles

• Dasatinib-Blinatumomab for Ph-Positive ALL. Reply.

  Foà R, Chiaretti S. Foà R, et al. N Engl J Med. 2021 Jan 28;384(4):384. doi: 10.1056/NEJMc2033785. N Engl J Med. 2021. PMID: 33503352 No abstract available.
• Dasatinib-Blinatumomab for Ph-Positive Acute Lymphoblastic Leukemia in Adults.

  Foà R, Bassan R, Vitale A, Elia L, Piciocchi A, Puzzolo MC, Canichella M, Viero P, Ferrara F, Lunghi M, Fabbiano F, Bonifacio M, Fracchiolla N, Di Bartolomeo P, Mancino A, De Propris MS, Vignetti M, Guarini A, Rambaldi A, Chiaretti S; GIMEMA Investigators. Foà R, et al. N Engl J Med. 2020 Oct 22;383(17):1613-1623. doi: 10.1056/NEJMoa2016272. N Engl J Med. 2020. PMID: 33085860 Clinical Trial.
• Host immune system modulation in Ph+ acute lymphoblastic leukemia patients treated with dasatinib and blinatumomab.

  Puzzolo MC, Radice G, Peragine N, de Propris MS, Mariglia P, Vignetti M, Vitale A, Bassan R, Annunziata M, Gaidano G, Rambaldi A, Chiaretti S, Guarini A, Foà R. Puzzolo MC, et al. Blood. 2021 Dec 2;138(22):2290-2293. doi: 10.1182/blood.2021011822. Blood. 2021. PMID: 34297829 No abstract available.
• A review of blinatumomab, a novel immunotherapy.

  Newman MJ, Benani DJ. Newman MJ, et al. J Oncol Pharm Pract. 2016 Aug;22(4):639-45. doi: 10.1177/1078155215618770. Epub 2015 Nov 24. J Oncol Pharm Pract. 2016. PMID: 26607163 Review.
• Blinatumomab (Blincyto) for acute lymphoblastic leukemia.

  [No authors listed] [No authors listed] Med Lett Drugs Ther. 2015 May 11;57(1468):e74-5. Med Lett Drugs Ther. 2015. PMID: 25941958 Review.